Sol-Gel Technologies (NASDAQ: SLGL)
$0.89
(3.3%)
$0.03
Price as of April 26, 2024, 1:33 p.m. ET
Sol-Gel Technologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sol-Gel Technologies Company Info
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
News & Analysis
Featured Article
Is Sol-Gel Technologies a Buy?
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
Maxx Chatsko | Feb 3, 2020
Featured Article
Here's Why Sol-Gel Technologies Stock Is Soaring Today
The small-cap company announced promising results from a clinical trial.
Maxx Chatsko | Dec 31, 2019
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.